AMLXAmylyx Pharmaceuticals, Inc.

$1B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

-$665,000-100.6% YoY

Gross Profit

-$665,000100.0% margin

Operating Income

-$41M6113.4% margin

Net Income

-$38M5646.0% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

-259.9%

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$59M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$194M

Total Liabilities

$29M

Stockholders' Equity

$165M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	-$665,000	$108M	-100.6%
Gross Profit	-$665,000	$99M	-100.7%
Operating Income	-$41M	$2M	-2202.1%
Net Income	-$38M	$5M	-893.6%

AMLX Q4 2024 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena